Head-To-Head Comparison: Oncocyte (IMDX) vs. The Competition

Oncocyte (NASDAQ:IMDX) is one of 860 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Oncocyte to related businesses based on the strength of its risk, dividends, institutional ownership, earnings, profitability, analyst recommendations and valuation.

Analyst Recommendations

This is a summary of recent ratings and price targets for Oncocyte and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1	0	2	0	2.33
Oncocyte Competitors	9357	14863	44502	1505	2.54

Oncocyte currently has a consensus price target of $10.50, suggesting a potential upside of 161.85%. As a group, “Biotechnology” companies have a potential upside of 56.86%. Given Oncocyte’s higher probable upside, equities research analysts plainly believe Oncocyte is more favorable than its peers.

Insider & Institutional Ownership

55.3% of Oncocyte shares are owned by institutional investors. Comparatively, 48.0% of shares of all “Biotechnology” companies are owned by institutional investors. 2.2% of Oncocyte shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Oncocyte and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,955.63%	N/A	-107.52%
Oncocyte Competitors	-9,425.07%	-127.38%	-33.07%

Volatility and Risk

Oncocyte has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, Oncocyte’s peers have a beta of 1.25, indicating that their average stock price is 25% more volatile than the S&P 500.

Valuation & Earnings

This table compares Oncocyte and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oncocyte	$4.05 million	-$50.22 million	-2.69
Oncocyte Competitors	$688.97 million	$9.83 million	-11.81

Oncocyte’s peers have higher revenue and earnings than Oncocyte. Oncocyte is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Oncocyte beats its peers on 7 of the 13 factors compared.

Oncocyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.